AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers

Yuki Moritoki, Zhe Xiong Lian, Heike Wulff, Guo Xiang Yang, Ya Hui Chuang, Ruth Y. Lan, Yoshiyuki Ueno, Aftab A. Ansari, Ross L. Coppel, Ian R. Mackay, M. Eric Gershwin

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

We previously reported that peripheral blood mononuclear cells (PBMCs) from patients with primary biliary cirrhosis (PBC) produce significantly higher levels of polyclonal IgM than controls after exposure to CpG. Furthermore, the prevalence and unusually high levels of antimitochondrial antibodies (AMAs) in patients with PBC suggest a profound loss of B cell tolerance. We have addressed the issue of whether CpG will promote the production ofAMAs and whether new experimental agents that inhibit the lymphocyte potassium channels Kv1.3 and KCa3.1 can suppress CpG-mediated B cell activation and AMA production. PBMCs were stimulated with and without CpG and were subsequently analyzed for phenotype, including expression of TLR9, CD86, and KCa3.1 concurrent with measurements of AMA and responses to a control antigen, tetanus toxoid, in supernatant. Additionally, K+ channel expression on B cells from PBC patients and controls was studied using whole-cell patch-clamp technology. In patients with PBC, CpG induces secretion of AMAs in PBMCs and also up-regulates B cell expression of TLR9, CD86, and KCa3.1. Additionally, K+ channel blockers suppress secretion of AMA without a reduction of CpG-B- enhanced IgM production. Furthermore, there is diminished up-regulation of TLR9 and CD86 without affecting proliferation of B cells, B cell apoptosis, or viability. Conclusion: These data suggest that the hyperresponsiveness of B cells in PBC accelerates B cell-mediated autoimmunity.

Original languageEnglish (US)
Pages (from-to)314-322
Number of pages9
JournalHepatology
Volume45
Issue number2
DOIs
StatePublished - Feb 2007

Fingerprint

Potassium Channel Blockers
Biliary Liver Cirrhosis
Antibody Formation
B-Lymphocytes
Ligands
Blood Cells
Immunoglobulin M
Kv1.3 Potassium Channel
Antibodies
Up-Regulation
Tetanus Toxoid
Autoimmunity
Lymphocytes
Apoptosis
Technology
Phenotype
Antigens

ASJC Scopus subject areas

  • Hepatology

Cite this

AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers. / Moritoki, Yuki; Lian, Zhe Xiong; Wulff, Heike; Yang, Guo Xiang; Chuang, Ya Hui; Lan, Ruth Y.; Ueno, Yoshiyuki; Ansari, Aftab A.; Coppel, Ross L.; Mackay, Ian R.; Gershwin, M. Eric.

In: Hepatology, Vol. 45, No. 2, 02.2007, p. 314-322.

Research output: Contribution to journalArticle

Moritoki, Y, Lian, ZX, Wulff, H, Yang, GX, Chuang, YH, Lan, RY, Ueno, Y, Ansari, AA, Coppel, RL, Mackay, IR & Gershwin, ME 2007, 'AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers', Hepatology, vol. 45, no. 2, pp. 314-322. https://doi.org/10.1002/hep.21522
Moritoki, Yuki ; Lian, Zhe Xiong ; Wulff, Heike ; Yang, Guo Xiang ; Chuang, Ya Hui ; Lan, Ruth Y. ; Ueno, Yoshiyuki ; Ansari, Aftab A. ; Coppel, Ross L. ; Mackay, Ian R. ; Gershwin, M. Eric. / AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers. In: Hepatology. 2007 ; Vol. 45, No. 2. pp. 314-322.
@article{fec95c1777164322bda9b85328c01b72,
title = "AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers",
abstract = "We previously reported that peripheral blood mononuclear cells (PBMCs) from patients with primary biliary cirrhosis (PBC) produce significantly higher levels of polyclonal IgM than controls after exposure to CpG. Furthermore, the prevalence and unusually high levels of antimitochondrial antibodies (AMAs) in patients with PBC suggest a profound loss of B cell tolerance. We have addressed the issue of whether CpG will promote the production ofAMAs and whether new experimental agents that inhibit the lymphocyte potassium channels Kv1.3 and KCa3.1 can suppress CpG-mediated B cell activation and AMA production. PBMCs were stimulated with and without CpG and were subsequently analyzed for phenotype, including expression of TLR9, CD86, and KCa3.1 concurrent with measurements of AMA and responses to a control antigen, tetanus toxoid, in supernatant. Additionally, K+ channel expression on B cells from PBC patients and controls was studied using whole-cell patch-clamp technology. In patients with PBC, CpG induces secretion of AMAs in PBMCs and also up-regulates B cell expression of TLR9, CD86, and KCa3.1. Additionally, K+ channel blockers suppress secretion of AMA without a reduction of CpG-B- enhanced IgM production. Furthermore, there is diminished up-regulation of TLR9 and CD86 without affecting proliferation of B cells, B cell apoptosis, or viability. Conclusion: These data suggest that the hyperresponsiveness of B cells in PBC accelerates B cell-mediated autoimmunity.",
author = "Yuki Moritoki and Lian, {Zhe Xiong} and Heike Wulff and Yang, {Guo Xiang} and Chuang, {Ya Hui} and Lan, {Ruth Y.} and Yoshiyuki Ueno and Ansari, {Aftab A.} and Coppel, {Ross L.} and Mackay, {Ian R.} and Gershwin, {M. Eric}",
year = "2007",
month = "2",
doi = "10.1002/hep.21522",
language = "English (US)",
volume = "45",
pages = "314--322",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers

AU - Moritoki, Yuki

AU - Lian, Zhe Xiong

AU - Wulff, Heike

AU - Yang, Guo Xiang

AU - Chuang, Ya Hui

AU - Lan, Ruth Y.

AU - Ueno, Yoshiyuki

AU - Ansari, Aftab A.

AU - Coppel, Ross L.

AU - Mackay, Ian R.

AU - Gershwin, M. Eric

PY - 2007/2

Y1 - 2007/2

N2 - We previously reported that peripheral blood mononuclear cells (PBMCs) from patients with primary biliary cirrhosis (PBC) produce significantly higher levels of polyclonal IgM than controls after exposure to CpG. Furthermore, the prevalence and unusually high levels of antimitochondrial antibodies (AMAs) in patients with PBC suggest a profound loss of B cell tolerance. We have addressed the issue of whether CpG will promote the production ofAMAs and whether new experimental agents that inhibit the lymphocyte potassium channels Kv1.3 and KCa3.1 can suppress CpG-mediated B cell activation and AMA production. PBMCs were stimulated with and without CpG and were subsequently analyzed for phenotype, including expression of TLR9, CD86, and KCa3.1 concurrent with measurements of AMA and responses to a control antigen, tetanus toxoid, in supernatant. Additionally, K+ channel expression on B cells from PBC patients and controls was studied using whole-cell patch-clamp technology. In patients with PBC, CpG induces secretion of AMAs in PBMCs and also up-regulates B cell expression of TLR9, CD86, and KCa3.1. Additionally, K+ channel blockers suppress secretion of AMA without a reduction of CpG-B- enhanced IgM production. Furthermore, there is diminished up-regulation of TLR9 and CD86 without affecting proliferation of B cells, B cell apoptosis, or viability. Conclusion: These data suggest that the hyperresponsiveness of B cells in PBC accelerates B cell-mediated autoimmunity.

AB - We previously reported that peripheral blood mononuclear cells (PBMCs) from patients with primary biliary cirrhosis (PBC) produce significantly higher levels of polyclonal IgM than controls after exposure to CpG. Furthermore, the prevalence and unusually high levels of antimitochondrial antibodies (AMAs) in patients with PBC suggest a profound loss of B cell tolerance. We have addressed the issue of whether CpG will promote the production ofAMAs and whether new experimental agents that inhibit the lymphocyte potassium channels Kv1.3 and KCa3.1 can suppress CpG-mediated B cell activation and AMA production. PBMCs were stimulated with and without CpG and were subsequently analyzed for phenotype, including expression of TLR9, CD86, and KCa3.1 concurrent with measurements of AMA and responses to a control antigen, tetanus toxoid, in supernatant. Additionally, K+ channel expression on B cells from PBC patients and controls was studied using whole-cell patch-clamp technology. In patients with PBC, CpG induces secretion of AMAs in PBMCs and also up-regulates B cell expression of TLR9, CD86, and KCa3.1. Additionally, K+ channel blockers suppress secretion of AMA without a reduction of CpG-B- enhanced IgM production. Furthermore, there is diminished up-regulation of TLR9 and CD86 without affecting proliferation of B cells, B cell apoptosis, or viability. Conclusion: These data suggest that the hyperresponsiveness of B cells in PBC accelerates B cell-mediated autoimmunity.

UR - http://www.scopus.com/inward/record.url?scp=33847702169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847702169&partnerID=8YFLogxK

U2 - 10.1002/hep.21522

DO - 10.1002/hep.21522

M3 - Article

C2 - 17256753

AN - SCOPUS:33847702169

VL - 45

SP - 314

EP - 322

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 2

ER -